• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Neuronetics Inc (NQ: STIM )

    1.130 +0.040 (+3.67%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Neuronetics Inc

    < Previous 1 2 3 4 5 6 Next >
    NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
    Data selected for oral presentation reinforce previous findings on safety and efficacy 
    From Neuronetics
    Via GlobeNewswire
    Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
    Policy update increases access for millions covered by HCSC BlueCross BlueShield policies 
    From Neuronetics
    Via GlobeNewswire
    Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
    BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression 
    From Neuronetics
    Via GlobeNewswire
    NeuroStar® Releases Software Upgrades to Elevate Patient Care
    Upgrades improve communication, streamline data management, and strengthen security 
    From Neuronetics
    Via GlobeNewswire
    Retractable Technologies And 2 Other Penny Stocks Executives Are Buying
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enstar Group Limited (Nasdaq – ESGR), PetIQ, Inc. (Nasdaq – PETQ), Greenbrook TMS, Inc. (OTC – GBNHF), GSE Solutions, Inc. (Nasdaq – GVP)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
    NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives 
    From Neuronetics
    Via GlobeNewswire
    Butterfly Network And 3 Other Stocks Under $2 Executives Are Aggressively Buying
    Via Benzinga
    NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
    Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility 
    From Neuronetics
    Via GlobeNewswire
    Gold Gains Over 1%; Starbucks Shares Move Higher
    Via Benzinga
    Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations
    Neuronetics to acquire Greenbrook TMS (OTC: GBNHF) in an all-stock deal, doubling revenue to $145M. The combined company expects mid-teens growth in 2025 and 2026, with $15M in cost savings and... 
    Via Benzinga
    Crude Oil Surges 2%; B. Riley Financial Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    STIM Stock Earnings: Neuronetics Misses EPS, Misses Revenue for Q2 2024
    STIM stock results show that Neuronetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Dow Dips 150 Points; Monday.com Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
    New initiative aims to provide information and resources for teen mental health amidst rising public health concerns 
    From Neuronetics
    Via GlobeNewswire
    Aetna Policy Update Expands TMS Availability for Adolescents With Depression
    Coverage criteria consistent with recent FDA clearance for NeuroStar TMS 
    From Neuronetics
    Via GlobeNewswire
    3 Neurotech Stocks Bridging Mind and Machine
    These neurotech stocks stand at the cutting edge of healthcare, but early entrants in new fields tend to be long-term winners. 
    Via InvestorPlace
    California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
    NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal 
    From Neuronetics
    Via GlobeNewswire
    BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents
    Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health 
    From Neuronetics
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Pre-market stock movers are worth checking out on Wednesday as we break down all of the biggest news worth reading this morning! 
    Via InvestorPlace
    NeuroStar® Launches Better Me Provider Program Nationwide
    The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry 
    From Neuronetics
    Via GlobeNewswire
    NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
    Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024 
    From Neuronetics
    Via GlobeNewswire
    Neuronetics And 3 Other Stocks Under $3 Insiders Are Buying
    Via Benzinga
    Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
    Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older 
    From Neuronetics
    Via GlobeNewswire
    Nasdaq Moves Lower; Great Lakes Dredge & Dock Shares Surge Following Upbeat Earnings
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Crude Oil Edges Lower; UBS Shares Jump After Q1 Earnings
    Via Benzinga
    Exposures Fossil Fuels
    Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    STIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024
    STIM stock results show that Neuronetics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
    The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance 
    From Neuronetics
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.